KilgourMD Secures Major Funding for Scalp Health Innovation
March 29, 2026, 5:07 pm
Location: United States, California, San Francisco
Employees: 11-50
Founded date: 2017
KilgourMD, a science-backed scalp health brand, announced significant Series A funding. Prelude Growth Partners spearheads this investment. The capital fuels expansion of proprietary ingredients. It accelerates new product development. It supports crucial clinical trials. Dr. James Kilgour, a board-certified dermatologist, founded the company in 2023. KilgourMD targets scalp aging as a root cause of hair thinning. Its clinically validated serums, shampoo, and conditioner address all genders. Successful trials on menopausal women highlight product efficacy. This funding positions KilgourMD for rapid market growth and innovation. It cements its leadership in advanced hair care, driving future solutions for diverse populations.
KilgourMD has closed a pivotal Series A funding round. This investment marks a significant milestone. Prelude Growth Partners led the capital injection. This firm is a prominent name in growth equity. They support consumer brands. Existing investors also participated. Willow Growth, Joyance Partners, and Able Partners reaffirmed their commitment. The precise amount raised remains undisclosed. This funding propels KilgourMD's mission forward. It aims to revolutionize scalp health and hair growth solutions.
Dr. James Kilgour founded KilgourMD in 2023. He is a Stanford-trained, board-certified dermatologist. His vision centers on scientific innovation. The company's focus is clear. It targets scalp aging. This process often underpins hair thinning. KilgourMD develops proprietary formulations. These solutions are clinically validated. They address hair loss across all genders and hair types. The brand emphasizes prevention and treatment. Its goal is long-term scalp and hair health.
The company's product portfolio is streamlined. It includes treatment and prevention serums. KilgourMD also offers specialized shampoo and conditioner. These products integrate seamlessly into daily routines. They are currently available exclusively online. Customers access solutions directly via kilgourmd.com. This direct-to-consumer approach fosters engagement. It builds a loyal customer base. Over one-third of customers recommend KilgourMD products. This demonstrates strong market traction.
KilgourMD saw a profitable 2025. This financial strength preceded the Series A round. The company also completed its first major clinical trial. This study focused on menopausal women. Participants used KilgourMD’s proprietary two-step scalp serum system. The results were compelling. Within six weeks, 95% of participants experienced decreased shedding. By four months, a majority achieved clinically meaningful regrowth. Two independent board-certified dermatologists validated these findings. The Journal of Drugs in Dermatology accepted these results for publication. This scientific validation underscores product efficacy. It reinforces KilgourMD's commitment to evidence-based solutions.
The new capital has a strategic deployment plan. KilgourMD will expand its proprietary active ingredient pipeline. This commitment drives future innovation. New product formulations are also a priority. The company plans to develop solutions for diverse hair concerns. Crucially, funds will support new clinical trials. These trials will target underserved populations in hair loss. This expands KilgourMD's reach. It addresses critical unmet needs in the hair care market. The investment ensures robust research and development.
Leadership changes accompany this funding. Alicia Sontag joins the company’s Board of Directors. She is Prelude Growth Partners’ Managing Partner. Her expertise will guide strategic growth. Dr. Kilgour remains a vital board member. Deborah Benton also serves on the board. She is Willow Growth's managing partner. Benton was the series seed lead investor. Dr. Alok Prasad, KilgourMD’s COO, completes the board. This diverse leadership team positions KilgourMD for accelerated expansion. Their collective experience will drive market leadership.
KilgourMD operates at a unique intersection. It bridges clinical dermatology and consumer hair care. This position allows for advanced, accessible solutions. The brand's focus on scalp aging is distinctive. It addresses a root cause, not just symptoms. This comprehensive approach sets KilgourMD apart. Its growth trajectory is steep. The company currently sells a bottle of scalp serum every 20 seconds. This metric highlights rapid customer adoption. It showcases strong product demand.
The future for KilgourMD appears bright. The Series A funding empowers ambitious initiatives. Expanding clinical research is paramount. Innovating new products remains a core objective. The company seeks to solidify its position. It aims to become the definitive powerhouse brand in scalp health. KilgourMD's scientific foundation supports this ambition. Its proven results build consumer trust. This strategic investment will fuel sustained growth. It promises advanced hair loss solutions for a broad audience. KilgourMD continues its mission to redefine scalp health standards. It delivers effective, science-backed hair care.
KilgourMD has closed a pivotal Series A funding round. This investment marks a significant milestone. Prelude Growth Partners led the capital injection. This firm is a prominent name in growth equity. They support consumer brands. Existing investors also participated. Willow Growth, Joyance Partners, and Able Partners reaffirmed their commitment. The precise amount raised remains undisclosed. This funding propels KilgourMD's mission forward. It aims to revolutionize scalp health and hair growth solutions.
Dr. James Kilgour founded KilgourMD in 2023. He is a Stanford-trained, board-certified dermatologist. His vision centers on scientific innovation. The company's focus is clear. It targets scalp aging. This process often underpins hair thinning. KilgourMD develops proprietary formulations. These solutions are clinically validated. They address hair loss across all genders and hair types. The brand emphasizes prevention and treatment. Its goal is long-term scalp and hair health.
The company's product portfolio is streamlined. It includes treatment and prevention serums. KilgourMD also offers specialized shampoo and conditioner. These products integrate seamlessly into daily routines. They are currently available exclusively online. Customers access solutions directly via kilgourmd.com. This direct-to-consumer approach fosters engagement. It builds a loyal customer base. Over one-third of customers recommend KilgourMD products. This demonstrates strong market traction.
KilgourMD saw a profitable 2025. This financial strength preceded the Series A round. The company also completed its first major clinical trial. This study focused on menopausal women. Participants used KilgourMD’s proprietary two-step scalp serum system. The results were compelling. Within six weeks, 95% of participants experienced decreased shedding. By four months, a majority achieved clinically meaningful regrowth. Two independent board-certified dermatologists validated these findings. The Journal of Drugs in Dermatology accepted these results for publication. This scientific validation underscores product efficacy. It reinforces KilgourMD's commitment to evidence-based solutions.
The new capital has a strategic deployment plan. KilgourMD will expand its proprietary active ingredient pipeline. This commitment drives future innovation. New product formulations are also a priority. The company plans to develop solutions for diverse hair concerns. Crucially, funds will support new clinical trials. These trials will target underserved populations in hair loss. This expands KilgourMD's reach. It addresses critical unmet needs in the hair care market. The investment ensures robust research and development.
Leadership changes accompany this funding. Alicia Sontag joins the company’s Board of Directors. She is Prelude Growth Partners’ Managing Partner. Her expertise will guide strategic growth. Dr. Kilgour remains a vital board member. Deborah Benton also serves on the board. She is Willow Growth's managing partner. Benton was the series seed lead investor. Dr. Alok Prasad, KilgourMD’s COO, completes the board. This diverse leadership team positions KilgourMD for accelerated expansion. Their collective experience will drive market leadership.
KilgourMD operates at a unique intersection. It bridges clinical dermatology and consumer hair care. This position allows for advanced, accessible solutions. The brand's focus on scalp aging is distinctive. It addresses a root cause, not just symptoms. This comprehensive approach sets KilgourMD apart. Its growth trajectory is steep. The company currently sells a bottle of scalp serum every 20 seconds. This metric highlights rapid customer adoption. It showcases strong product demand.
The future for KilgourMD appears bright. The Series A funding empowers ambitious initiatives. Expanding clinical research is paramount. Innovating new products remains a core objective. The company seeks to solidify its position. It aims to become the definitive powerhouse brand in scalp health. KilgourMD's scientific foundation supports this ambition. Its proven results build consumer trust. This strategic investment will fuel sustained growth. It promises advanced hair loss solutions for a broad audience. KilgourMD continues its mission to redefine scalp health standards. It delivers effective, science-backed hair care.